Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting a study titled ‘FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting.’ The study aims to gather real-world data on the use of finerenone, a drug prescribed for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This research is significant as it seeks to understand treatment patterns and outcomes in a routine medical care environment.
Intervention/Treatment: The study focuses on finerenone, marketed as Kerendia, which is a drug designed to block mineralocorticoid receptors. This action helps reduce kidney and heart damage risks in CKD and T2D patients.
Study Design: This is an observational cohort study with a prospective time perspective. It involves collecting data from medical records and interviews with participants who are newly prescribed finerenone. The primary purpose is to observe treatment patterns and outcomes in a real-world setting.
Study Timeline: The study began on June 13, 2022, and is currently recruiting participants. The primary completion and estimated study completion are expected by September 2027. The last update was submitted on August 5, 2025, indicating ongoing progress.
Market Implications: This study could positively influence Bayer’s stock performance by providing valuable insights into finerenone’s real-world effectiveness, potentially boosting investor confidence. As finerenone is relatively new in the market, this study may also impact competitor strategies and the broader pharmaceutical industry focused on CKD and T2D treatments.
The study is ongoing, and further details are available on the ClinicalTrials portal.